Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg/kg infusions of 3BNC117, separated by 3 or 2 weeks, respectively, were generally well tolerated. The infusions were associated with a delay in viral rebound for 5-9 weeks after 2 infusions, and up to 19 weeks after 4 infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (p=<1e-5). Rebound viruses arose predominantly from a single provirus. In most individuals, emerging viruses showed increased resistance indicating escape. However, 30% of participants remained suppressed until antibody concentrations waned below 20 μg/ml, and the viruses emerging in all but one of these individuals showed no apparent resistance to 3BCN117, suggesting failure to escape over a period of 9-19 weeks. We conclude that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.


  1. 1.

    et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, doi:science.1207227 [pii] 10.1126/science.1207227 (2011)

  2. 2.

    et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640, doi:nature07930 [pii] 10.1038/nature07930 (2009)

  3. 3.

    et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199–1204, doi:10.1126/science.1241144 (2013)

  4. 4.

    et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228, doi:10.1038/nature12744 (2013)

  5. 5.

    et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989–999, doi:10.1016/j.cell.2014.07.043 (2014)

  6. 6.

    et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118–122, doi:10.1038/nature11604 (2012)

  7. 7.

    et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America 110, 16538–16543, doi:10.1073/pnas.1315295110 (2013)

  8. 8.

    et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211, 2061–2074, doi:10.1084/jem.20132494 (2014)

  9. 9.

    et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491, doi:10.1038/nature14411 (2015)

  10. 10.

    et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997–1001, doi:10.1126/science.aaf0972 (2016)

  11. 11.

    et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001–1004, doi:10.1126/science.aaf1279 (2016)

  12. 12.

    et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. Journal of virology 89, 2659–2671, doi:10.1128/JVI.03136-14 (2015)

  13. 13.

    et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science translational medicine 7, 319ra206, doi:10.1126/scitranslmed.aad5752 (2015)

  14. 14.

    et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277–280, doi:10.1038/nature12746 (2013)

  15. 15.

    et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America 109, E3268–3277, doi:10.1073/pnas.1217207109 (2012)

  16. 16.

    et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proceedings of the National Academy of Sciences of the United States of America 112, E1126–1134, doi:10.1073/pnas.1414926112 (2015)

  17. 17.

    et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS pathogens 10, e1004010, doi:10.1371/journal.ppat.1004010 (2014)

  18. 18.

    et al. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses that are Transcriptionally Active Before Stopping Antiretroviral Therapy. Journal of virology, 10.1128/JVI.02139-15 (2015)

  19. 19.

    & , Katharine. Potency and Kinetics of Autologous HIV-1 Neutralizing Antibody Responses During ATI. CROI Conference Abstracts Abstract #92 (2016)

  20. 20.

    , , & Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America 109, E2083–2090, doi:10.1073/pnas.1208984109 (2012)

  21. 21.

    et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med 210, 1235–1249, doi:10.1084/jem.20130221 (2013)

  22. 22.

    et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. Journal of virology 89, 4201–4213, doi:10.1128/JVI.03608-14 (2015)

  23. 23.

    et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245–258, doi:10.1016/j.immuni.2013.04.012 (2013)

  24. 24.

    et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484–1490, doi:10.1126/science.1245627 (2013)

  25. 25.

    et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 10.1038/nature17677 (2016)

  26. 26.

    et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11, 615–622, doi:10.1038/nm1244 (2005)

  27. 27.

    et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. Journal of virology 81, 11016–11031, doi:10.1128/JVI.01340-07 (2007)

  28. 28.

    et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551, doi:10.1016/j.cell.2013.09.020 (2013)

  29. 29.

    et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343–353, doi:10.1097/QAD.0000000000000953 (2016)

  30. 30.

    Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. PNAS (2013)

  31. 31.

    et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS pathogens 9, e1003398, doi:10.1371/journal.ppat.1003398 (2013)

  32. 32.

    et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 23, 1987–1995, doi:10.1097/QAD.0b013e32832eb285 (2009)

  33. 33.

    et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). The Journal of infectious diseases 194, 1672–1676, doi:10.1086/509508 (2006)

  34. 34.

    et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. The Journal of infectious diseases 194, 623–632, doi:10.1086/506364 (2006)

  35. 35.

    et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557, doi:10.1126/science.1195271 (2010)

  36. 36.

    Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12, Unit 12 11, doi:10.1002/0471142735.im1211s64 (2005)

  37. 37.

    et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology 79, 10108–10125, doi:10.1128/JVI.79.16.10108-10125.2005 (2005)

  38. 38.

    et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. Journal of virology 82, 3952–3970, doi:10.1128/JVI.02660-07 (2008)

  39. 39.

    et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28, 1647–1649, doi:10.1093/bioinformatics/bts199 (2012)

  40. 40.

    , , & WebLogo: a sequence logo generator. Genome research 14, 1188–1190, doi:10.1101/gr.849004 (2004)

  41. 41.

    et al. High throughput functional analysis of HIV-1 env genes without cloning. Journal of virological methods 143, 104–111, doi:10.1016/j.jviromet.2007.02.015 (2007)

  42. 42.

    & Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Statistics in medicine 24, 3089–3110, doi:10.1002/sim.2174 (2005)

  43. 43.

    et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948, doi:btm404 [pii] 10.1093/bioinformatics/btm404 (2007)

  44. 44.

    & MacClade - Analysis of Phylogeny and Character Evolution - Version 4. (Sinauer Associates, Inc., 2001)

  45. 45.

    , , & jModelTest 2: more models, new heuristics and parallel computing. Nature methods 9, 772, doi:10.1038/nmeth.2109 (2012)

  46. 46.

    et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Systematic biology 59, 307–321, doi:10.1093/sysbio/syq010 (2010)

  47. 47.

    et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188, doi:10.1038/387183a0 (1997)

  48. 48.

    et al. Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America 110, 6626–6633, doi:10.1073/pnas.1304288110 (2013)

  49. 49.

    & Recco: recombination analysis using cost optimization. Bioinformatics 22, 1064–1071, doi:10.1093/bioinformatics/btl057 (2006)

  50. 50.

    & A note on two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics 68, 1323–1326; author reply 1326, doi:10.1111/j.1541-0420.2012.01775.x (2012)

  51. 51.

    et al. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. Journal of virology 74, 8541–8549 (2000)

  52. 52.

    et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. Journal of virology 77, 2081–2092 (2003)

Download references


We would like to thank the trial participants for their invaluable support; We thank the Rockefeller University Hospital Clinical Research Support Office and nursing staff for help with recruitment and study implementation, especially Noreen Buckley, Arlene Hurley, Sivan Ben Avraham Shulman and Lauren Corregano. All members of the Nussenzweig lab, especially Till Schoofs, Ari Halper-Stromberg, Mila and Zoran Jankovic. Cecille Unson-O'Brien, Juan Dizon, Renise Baptiste and Rebeka Levin for sample processing and study coordination; Audrey Louie for regulatory support; Pat Fast and Harriet Park for clinical monitoring. Elena Giorgi and William Fischer from Los Alamos National Laboratory. Rajesh Tim Gandhi, Jonathan Li and The AIDS Clinical Trials Group (grant UM1 AI068636) and its Statistical and Data Management Center (grant UM1 AI068634). This study was supported by the following grants: Collaboration for AIDS Vaccine Discovery grant OPP1033115 (M.C.N.) and OPP1032144 (M.S.S.). Grant 8 UL1 TR000043 from the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program; NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) 1UM1 AI100663-01 (M.C.N) and 5UM1 AI100645-03 (B.H.H.); Bill and Melinda Gates Foundation grants OPP1092074 and OPP1124068 (M.C.N); NIH HIVRAD P01 AI100148 (PJB and MCN); the Robertson Foundation to M.C.N. M.C.N. is a Howard Hughes Medical Institute Investigator. Ruth L. Kirschstein National Research Service Award. F30 AI112426 (E.F.K); F31 AI118555 (J.A.H.); The NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) 1UM1 AI00645 (B.H.H.); The University of Pennsylvania Center for AIDS Research (CFAR) Single Genome Amplification Service Center P30 AI045008 (B.H.H.); The NIH Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID and 1UM1-AI100663) (B.D.W).

Author information

Author notes

    • Johannes F. Scheid
    •  & Joshua A. Horwitz

    These authors contributed equally to this work.


  1. Laboratory of Molecular Immunology, and 14Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065

    • Johannes F. Scheid
    • , Joshua A. Horwitz
    • , Yotam Bar-On
    • , Ching-Lan Lu
    • , Julio C. C. Lorenzi
    • , Malte Braunschweig
    • , Lilian Nogueira
    • , Thiago Oliveira
    • , Irina Shimeliovich
    • , Roshni Patel
    • , Yehuda Z. Cohen
    • , Sonya Hadrigan
    • , Allison Settler
    • , Maggi Witmer-Pack
    • , Florian Klein
    • , Sarah J. Schlesinger
    • , Michel C. Nussenzweig
    •  & Marina Caskey
  2. Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114

    • Johannes F. Scheid
  3. Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104

    • Edward F. Kreider
    • , Gerald H. Learn
    •  & Beatrice H. Hahn
  4. Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Campus E1 4, 66123 Saarbrücken, Germany

    • Anna Feldmann
    •  & Nico Pfeifer
  5. Division of Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10065, USA

    • Leah Burke
    •  & Roy M. Gulick
  6. Division of Biology, California Institute of Technology, Pasadena, California 91125

    • Anthony P. West, Jr.
    •  & Pamela J. Bjorkman
  7. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA

    • Boris Juelg
    •  & Bruce D. Walker
  8. Celldex Therapeutics, Inc., Hampton, NJ 08827, USA

    • Tibor Keler
    •  & Thomas Hawthorne
  9. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467

    • Barry Zingman
  10. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215

    • Michael S. Seaman
  11. Laboratory of Experimental Immunology, Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany

    • Florian Klein
  12. Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, 50937 Cologne, Germany

    • Florian Klein
  13. Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, MA 02114

    • Bruce D. Walker
    •  & Michel C. Nussenzweig


  1. Search for Johannes F. Scheid in:

  2. Search for Joshua A. Horwitz in:

  3. Search for Yotam Bar-On in:

  4. Search for Edward F. Kreider in:

  5. Search for Ching-Lan Lu in:

  6. Search for Julio C. C. Lorenzi in:

  7. Search for Anna Feldmann in:

  8. Search for Malte Braunschweig in:

  9. Search for Lilian Nogueira in:

  10. Search for Thiago Oliveira in:

  11. Search for Irina Shimeliovich in:

  12. Search for Roshni Patel in:

  13. Search for Leah Burke in:

  14. Search for Yehuda Z. Cohen in:

  15. Search for Sonya Hadrigan in:

  16. Search for Allison Settler in:

  17. Search for Maggi Witmer-Pack in:

  18. Search for Anthony P. West, Jr. in:

  19. Search for Boris Juelg in:

  20. Search for Tibor Keler in:

  21. Search for Thomas Hawthorne in:

  22. Search for Barry Zingman in:

  23. Search for Roy M. Gulick in:

  24. Search for Nico Pfeifer in:

  25. Search for Gerald H. Learn in:

  26. Search for Michael S. Seaman in:

  27. Search for Pamela J. Bjorkman in:

  28. Search for Florian Klein in:

  29. Search for Sarah J. Schlesinger in:

  30. Search for Bruce D. Walker in:

  31. Search for Beatrice H. Hahn in:

  32. Search for Michel C. Nussenzweig in:

  33. Search for Marina Caskey in:


M.C.N, J.F.S, J.A.H and M.C wrote the manuscript; J.F.S, M.C and M.C.N designed the trial; J.F.S, J.A.H, Y.B, J.C.C.L, L.N, Y.Z.C, C-L.L and M.B performed tissue culture experiments and SGS amplifications; M.S.S performed TZM-bl assays; J.F.S, J.A.H, Y.B, E.F.K, T.O, A.P.W, G.H.L, P.J.B, F.K, S.J.S, B.H.H, M.C.N and M.C analyzed the data; E.F.K, G.H.L and B.H.H performed SGA analysis; I.S, R.P and J.F.S processed patient samples; L.B, S.H, A.S, M.W-P, B.Z, R.M.G, S.J.S and M.C performed patient recruitment; A.F and N.P performed statistical analyses; B.J and B.D.W performed antigen specific T cell experiments; T.K and T.H produced 3BNC117 and provided PK data.

Competing interests

There are pending patent applications on the 3BNC117 and 10-1074 antibodies by Rockefeller University on which M.C.N. and J.F.S. are inventors. The patents are not licensed by any companies. Neither M.C.N. nor J.F.S. have any competing financial interests.

Corresponding authors

Correspondence to Michel C. Nussenzweig or Marina Caskey.

There are pending patent applications on the 3BNC117 and 10-1074 antibodies by Rockefeller University on which M.C.N and J.F.S are inventors. The patents are not licensed by any companies.

Reviewer Information Nature thanks S. Deeks, D. Richman and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains supplementary Figures 1-2, Supplementary Tables 1-9 and Supplementary References. This file was updated on 27 July 2016 to correct the reference list.

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.